Trial Profile
A double-blind randomized clinical trial comparing the safety and antiviral activity of 48-week clevudine and adefovir-dipivoxil in HBeAg(-) [hepatitis e antigen negative] chronic hepatitis b with compensated liver function.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 30 Apr 2012
Price :
$35
*
At a glance
- Drugs Clevudine (Primary) ; Adefovir dipivoxil
- Indications Hepatitis B
- Focus Therapeutic Use
- Sponsors Bukwang Pharmaceutical
- 24 Apr 2012 Actual patient number is 43 according to ClinicalTrials.gov.
- 24 Apr 2012 Actual end date (Mar 2012) added as reported by ClinicalTrials.gov.
- 24 Apr 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.